Addyi was initial accredited by the FDA in August 2015 to treat hypoactive sexual wish problem (HSDD) in premenopausal women. That is just another way of claiming it boosts intercourse travel (also known as libido) in women that have not attained menopause. It had been the primary these types of drug approved for this use.WHO also incorporates cond